Status:
COMPLETED
Prospective Study on the Use of Transdermal Analgesic Buprenorphine Patches for Chronic Pain in the UK
Lead Sponsor:
Mundipharma Research Limited
Conditions:
Chronic Pain
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of the study is the descriptive analysis of incidence \& severity of side effects \& reasons for discontinuation of the treatment of chronic pain with transdermal analgesic Bupre...
Detailed Description
750 patients that are treated with transdermal Buprenorphine patches for chronic pain will be included in the study. About 20% of patients are aimed to be patch-naive, ie have received their first pre...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patient age \> 18
- Patient is treated with transdermal Buprenorphine
- The patient is able to answer the patient's survey \& has an estimated overall survival of minimum 6 months
- The patient gives his/her informed, written consent to participate in the study
- Exclusion Criteria
- Patient Age \< 18
- Patient has less than 6 months survival expectancy
- Patient is unable to answer the patient survey for whatever reason in any feasible form
Exclusion
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2014
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT01225861
Start Date
November 1 2010
End Date
January 1 2014
Last Update
May 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Western Infirmary, Terrent Institute
Glasgow, United Kingdom, G11 6NT